• 中国科学论文统计源期刊
  • 中国科技核心期刊
  • 美国化学文摘(CA)来源期刊
  • 日本科学技术振兴机构数据库(JST)

临床输血与检验 ›› 2019, Vol. 21 ›› Issue (5): 517-520.DOI: 10.3969/j.issn.1671-2587.2019.05.021

• 临床检验 • 上一篇    下一篇

化疗联合内分泌疗法对Luminal A型乳腺癌的疗效及生存期的影响分析

陈园   

  1. 072750 保定市第二中心医院
  • 收稿日期:2018-04-04 出版日期:2019-10-20 发布日期:2019-10-29
  • 作者简介:陈园(1982-),女,河北保定人,主治医师,硕士,主要从事化疗联合内分泌疗法方面研究,(Tel)13931272090。

Efficacy of Chemotherapy Combined with Endocrinotherapy in Patients with Luminal A Breast Cancer

CHEN Yuan   

  1. Baoding Second Central Hospital,Baoding 072750
  • Received:2018-04-04 Online:2019-10-20 Published:2019-10-29

摘要: 目的 探讨化疗联合内分泌疗法在LuminalA型乳腺癌患者中的临床效果及对生存期的影响。方法 选择2015年6月~2017年7月科室收治的LuminalA型乳腺癌患者84例,采用随机数字法分为对照组(n=42例)和观察组(n=42例)。对照组采用单纯化疗治疗,观察组在对照组基础上联合他莫昔芬内分泌治疗,采用流式细胞仪测定两组治疗前后CD3+、CD4+、CD8+和CD4+/CD8+水平;采用流式细胞仪测定两组治疗前后干扰素-r(IFN-r)、肿瘤坏死因子-a(TNF-a)、白细胞介素-4(IL-4)和白细胞介素-10(IL-10)水平,记录两组治疗后不同时间点生存期情况,比较两组临床疗效及对生存期的影响。结果 观察组治疗2周期疗效率为64.29%,与对照组47.62%比较差异无统计学意义(χ2=2.367,P>0.05);观察组治疗后2周期CD3+/CD4+CD8+和CD4+/CD8+水平均高于对照组(t=18.486、14.581,P<0.05);观察组治疗后2周期CD3+/CD8+低于对照组(t=11.295,P<0.05);观察组治疗后2周期IL-4和IL-10水平低于对照组(t=8.385、9.132、14.681、15.773,P<0.05);两组治疗后1年、3年、5年生存率比较差异无统计学意义(χ2=0.994、1.556、1.365,P>0.05)。结论 将化疗联合他莫昔芬内分泌治疗用于LuminalA型乳腺癌患者有助于提高机体免疫、降低炎症因子水平、延长患者生存期,值得推广应用。

关键词: 单纯化疗, 内分泌疗法, LuminalA型乳腺癌, 流式细胞仪炎, 症因子, 生存期

Abstract: Objective To investigate the clinical effect of patients with Luminal A breast cancer treated with chemotherapy and endocrine therapy.Methods A total of 84 patients with Luminal A type breast cancer were observed in 2015 and 2017. The patients were randomly divided into control group (n=42) and observation group (n=42). The control patients were treated with chemotherapy alone whereas those for observation were treated in combination with tamoxifen endocrine therapy. CD3+,CD4+,CD8+,and CD4+/CD8+cells were measured by flow cytometry pre- and post- treatment. Simultaneously,IFN-γ,TNF-α,IL-4,and IL-10 cytokines were detected. The survival time at different time points after treatments was compared for the clinical efficacy in the two groups.Results No significant difference was noted in the efficacy rate between the treatment group (64.29%) and the control (47.62%) (P>0.05). The number of CD3+/CD4+CD8+ and CD4+/CD8+cells in the group of combination treatments was increased when compared with the control (P<0.05). But the CD3+/CD8+cell counts as well as IL-10 in the combination group were lower than in the control ( P<0.05). No significant difference,however,was found in survival rates of 1yr,3yr,and 5yr between the two groups (P>0.05).Conclusion The combination of chemotherapy and tamoxifen endocrinotherapy in patients with Luminal A type breast cancer may help improve the immunity,inhibit inflammatory factors and prolong the survival of patients.

Key words: Chemotherapy, Endocrine therapy, Luminal A breast cancer, Flow cytometry, Inflammatory cutokines, Sunbibal

中图分类号: